Back to Supplement Finder

VIP - Vasoactive Intestinal Peptide X 5mg

Sold by FMI Health

INR 9,304.00

View at FMI Health
Store
fmihealth.com
Brand
Biolongevity Labs
Product type
Peptides
Collected
2026-11-20

From the retailer

Retailer description retrieved 2026-11-20. Claims are the retailer’s, not independently verified.

Description--VIP is a 28‑amino acid regulatory hormone peptide that controls smooth muscle relaxation and secretion processes across multiple biological systems. It plays a central role in cellular signaling, vascular function, and secretory regulation, making it a valuable research tool for investigating therapeutic pathways in controlled laboratory settings.

 

Mechanistic Claims

  • Smooth Muscle Regulation: Mediates relaxation of vascular, gastrointestinal, and respiratory smooth muscle.
  • Secretory Control: Influences secretion in endocrine and exocrine tissues.
  • Cellular Signaling: Acts through G‑protein coupled receptors to regulate cyclic AMP pathways.
  • Vascular Function: Supports vasodilation and blood flow regulation.
  • Neuroprotective & Immunomodulatory Potential: Explored for roles in inflammation, immune balance, and neuronal signaling.

 

Research Applications

  • Vascular biology and vasodilation studies
  • Smooth muscle physiology investigations
  • Secretory pathway and endocrine/exocrine regulation models
  • Neuroprotection and immunomodulation research
  • Exploratory therapeutic studies in inflammation and respiratory health

 

VIP Research Insights

  • 28‑amino acid peptide hormone with broad systemic regulatory roles.
  • Studied for effects on smooth muscle, vascular tone, and secretory activity.
  • Research highlights potential in immune modulation, neuroprotection, and inflammation control.
  • Supplied in pharmaceutical‑grade, lyophilized form to ensure purity and stability.
  • Recommended handling: reconstitute with bacteriostatic water immediately before use; aliquot single‑use portions; store at ≤ –20 °C to avoid repeated freeze–thaw cycles.


VIP Research

VIP research spans multiple biological systems, offering laboratories diverse opportunities to study this 28-amino acid peptide’s regulatory mechanisms.

 

Cardiovascular Research

VIP acts as a potent vasodilator by binding to VPAC receptors and increasing nitric oxide production. Laboratory studies show VIP influences coronary blood flow and heart rate regulation through its presence in cardiac nerve fibers[1].

 

Digestive System Studies

Research demonstrates VIP’s role in gut motility regulation through smooth muscle relaxation in the esophageal sphincter and stomach. The peptide stimulates pancreatic secretion of water and electrolytes while inhibiting gastric acid production[2].

 

Immune System Investigations

VIP exhibits anti-inflammatory properties by binding to VPAC1 and VPAC2 receptors on immune cells. Studies show the peptide inhibits T-cell proliferation and suppresses inflammatory cytokine production from macrophages and microglia[3].

 

Neurological Research

Laboratory investigations reveal VIP’s neuroprotective effects on dopaminergic neurons through microglial modulation. The peptide plays a central role in circadian rhythm regulation via VPAC2 receptor activation in the suprachiasmatic nucleus[4].

 

Receptor Mechanisms

VIP research focuses on VPAC1 and VPAC2 receptor interactions that trigger adenylate cyclase activation and cAMP elevation[5]. These signaling cascades activate protein kinase A pathways across different cell types[6].

 

References

  1. R. Henning, “Vasoactive intestinal peptide: cardiovascular effects,” Oxford University Press (OUP), Jan. 2001. doi: 10.1016/s0008-6363(00)00229-7. 
  2. M. Iwasaki, Y. Akiba, and J. D. Kaunitz, “Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system,” F1000 Research Ltd, Sep. 2019. doi: 10.12688/f1000research.18039.1. 
  3. C. Martínez et al., “A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases,” MDPI AG, Dec. 2019. doi: 10.3390/ijms21010065. https://doi.org/10.3390/ijms21010065
  4. J. Fahrenkrug, “Transmitter Role of Vasoactive Intestinal Peptide,” Wiley, Jun. 1993. doi: 10.1111/j.1600-0773.1993.tb01344.x. 
  5. I. Langer, “Mechanisms involved in VPAC receptors activation and regulation: lessons from pharmacological and mutagenesis studies,” Frontiers Media SA, 2012. doi: 10.3389/fendo.2012.00129. 
  6. I. Kato et al., “Transgenic mice overexpressing human vasoactive intestinal peptide (VIP) gene in pancreatic beta cells. Evidence for improved glucose tolerance and enhanced insulin secretion by VIP and PHM-27 in vivo.,”Journal of Biological Chemistry, vol. 269 33, pp. 21223–8, 1994.



Label--Peptide Information

Property Value
Peptide Sequence His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2
Molecular Formula C147H238N44O42S
Molecular Weight 3325.8 g/mol
CAS Number 40077-57-4
PubChem CID 53314964
Synonyms VIP, Aviptadil, Vasoactive Intestinal Polypeptide, Vasoactive Intestinal Peptide


Dosage--This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY.